Today it was reported that the CFO of OptimizeRx Corporation (OPRX), Douglas Baker, exercised options to buy 5,000 OPRX shares at $3.15 a share, for a total transaction value of $15.75K.
Following this transaction Douglas Baker’s holding in the company was increased by 18.6% to a total of $383.9K. In addition to Douglas Baker, 2 other OPRX executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on OptimizeRx Corporation’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $5.42 million and quarterly net profit of $244.9K. In comparison, last year the company earned revenue of $4.01 million and had a GAAP net loss of $237.1K. Currently, OptimizeRx Corporation has an average volume of 174.9K. The Company has a Price to Book ratio of 8.3776.
Starting in June 2018, OPRX received 11 Buy ratings in a row.
The insider sentiment on OptimizeRx Corporation has been positive according to 24 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Douglas Baker’s trades have generated a 46.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OptimizeRx Corp. engages in the provision of digital health messaging via electronic health records (EHR), which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. Its services include EHR workflow solutions such as financial messaging, patient education, and brand messaging; and brand support.
